LACE-Bio

Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

LACE-Bio Steering Committee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.

Original languageEnglish (US)
Pages (from-to)66-73.e6
JournalClinical Lung Cancer
Volume20
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
Immunohistochemistry
Patient Selection
Adjuvant Chemotherapy
Tissue Fixation
Tumor-Infiltrating Lymphocytes
Survival
Tubulin
Cisplatin
Lung Neoplasms
Leukemia
Lung
Antibodies
Neoplasms

Keywords

  • Adjuvant chemotherapy
  • Biomarkers
  • NSCLC
  • Predicative
  • Prognostic

PubMed: MeSH publication types

  • Clinical Trial
  • Journal Article
  • Validation Studies

Cite this

LACE-Bio : Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer. / LACE-Bio Steering Committee.

In: Clinical Lung Cancer, Vol. 20, No. 2, 01.03.2019, p. 66-73.e6.

Research output: Contribution to journalArticle

@article{b7b3774187184f82b76e06d4152e7bac,
title = "LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer",
abstract = "There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.",
keywords = "Adjuvant chemotherapy, Biomarkers, NSCLC, Predicative, Prognostic",
author = "{LACE-Bio Steering Committee} and Lesley Seymour and {Le Teuff}, Gw{\'e}na{\"e}l and Elisabeth Brambilla and Shepherd, {Frances A.} and Soria, {Jean Charles} and Kratzke, {Robert A} and Stephen Graziano and Douillard, {Jean Yves} and Rafael Rosell and Anthony Reiman and Benjamin Lacas and Beranger Lueza and Sarit Aviel-Ronen and Anne McLeer and {Le Chevalier}, Thierry and Robert Pirker and Martin Filipits and Ariane Dunant and Pignon, {Jean Pierre} and Tsao, {Ming Sound}",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.cllc.2018.10.001",
language = "English (US)",
volume = "20",
pages = "66--73.e6",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - LACE-Bio

T2 - Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer

AU - LACE-Bio Steering Committee

AU - Seymour, Lesley

AU - Le Teuff, Gwénaël

AU - Brambilla, Elisabeth

AU - Shepherd, Frances A.

AU - Soria, Jean Charles

AU - Kratzke, Robert A

AU - Graziano, Stephen

AU - Douillard, Jean Yves

AU - Rosell, Rafael

AU - Reiman, Anthony

AU - Lacas, Benjamin

AU - Lueza, Beranger

AU - Aviel-Ronen, Sarit

AU - McLeer, Anne

AU - Le Chevalier, Thierry

AU - Pirker, Robert

AU - Filipits, Martin

AU - Dunant, Ariane

AU - Pignon, Jean Pierre

AU - Tsao, Ming Sound

PY - 2019/3/1

Y1 - 2019/3/1

N2 - There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.

AB - There are no validated molecular tools to allow patient selection for adjuvant chemotherapy after complete resection of non–small-cell lung cancer. Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. The majority of the promising biomarkers could not be validated, and none were predictive of benefit. Immunohistochemistry assays from single trials may be misleading. Background: Complete resection of non–small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection. Materials and Methods: The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested. Results: The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches. Conclusions: Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.

KW - Adjuvant chemotherapy

KW - Biomarkers

KW - NSCLC

KW - Predicative

KW - Prognostic

UR - http://www.scopus.com/inward/record.url?scp=85055967423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055967423&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.10.001

DO - 10.1016/j.cllc.2018.10.001

M3 - Article

VL - 20

SP - 66-73.e6

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -